International IBD Genetics Consortium

PRED4

Thiopurine Hypersensitivity Reaction

Case Report Form

Study Code

Please stick study label here

On completion, please return to:

Exeter IBD Pharmacogenetics Research Office
The Research, Innovation, Learning and Development Centre (RILD)

Barrack Road

Exeter

EX2 5DW

Thiopurine Hypersensitivity Reaction Introduction

Please complete all boxes where indicated and in black ball point pen.

If you make a mistake please put a line through the box, initial and date and write answer to the side.

Complete dates in format dd/mm/yyyy

The patient identification number is the bar code on the front of the CRF. Please transcribe this on to the top of the page in each relevant section.

For study inclusion participants must meet all the major criteria.

Section 1 - Inclusion Criteria Study code

1.1	Inclusion criteria (all must be met)					
	Aged 6 years or over					
	History of inflammatory bowel disease					
History of thiopurine exposure in the previous 7 days before the onset of adver event						
	Flu-like symptoms severe enough to lead to drug withdrawal even if temporary (symptoms should include one of the following: fever, muscle ache, joint pain)					
	Onset of hypersensitivity reaction within 4 weeks of starting thiopurine					
	Symptoms of hypersensitivity reaction resolved within 14 days of drug withdrawal (for historical cases, please use clinical judgement when defining this inclusion)					
1.2	Exclusion criteria					
	Patient tolerated re-challenge with the same thiopurine regardless of dose					
	Drug withdrawn due to nausea and/or diarrhoea without any other symptoms					
	Objective evidence of infection at the time of the onset of hypersensitivity reaction					
1.3	Participant's eligibility					
Is th	e participant eligible to take part in the research project based on the above criteria?					
	Yes No					
If no	, please give reason(s) for screen failure:					
1.						
2.						
3.						
Inve	stigator's name (print) Date dd / mm / yyyy					

Section 2 - Patient Details Study code 2.1 Patient details Date of Birth Sex: M Weight at time of hypersensitivity reaction kg Date of weight Height cm **2.2 Ethnicity** - Please tick as appropriate White Black or Black British British Caribbean African Irish Any other White background Any other Black background Mixed **Chinese or Other Ethnic Group** White and Black Caribbean Chinese White and Black African Any other ethnic group (please specify) White and Asian Any other Mixed background Not stated Asian or Asian background Indian **Pakistani** Bangladeshi Any other Asian background 2.3 Participant informed consent Date participant signed written consent form Date of blood sample taken Name of person taking consent (print) Designation

Hospital name

Section 3 - Medical History		study code	
3.1 Other significant medical history If yes, please give details here	Yes	No	
3.2 Smoking history			
Never smoked Ex-smoke	er 🗌	Current smok	er
3.2.1 Start date dd / mm / yyyy	3.2.2 End	date	dd / mm / yyyy
3.2.3 Maximum number of cigarettes per day	<i>y</i>		

Section 4 - Diagnosis & Classification of IBD Study code 4.1 Diagnosis and classification of IBD Crohn's disease Date of diagnosis **Ulcerative Colitis** Date of diagnosis **IBD** unclassified Date of diagnosis 4.2 Ulcerative colitis 4.2.1 The extent of ulcerative colitis can be classified as: E1 Ulcerative proctitis E2 Left sided UC (distal UC) E3 Extensive UC (pancolitis) Ex Unknown 4.2.2 Disease severity in 2 years prior to development of hypersensitivity reaction **DS0** Clinical remission **DS1** Mild relapses DS2 Moderate relapse DS3 Severe or refractory disease requiring inpatient admission or colectomy 4.3 Crohn's disease 4.3.1 Location L1 Ileal L3 Ileocolonic L4 Isolated upper disease L2 Colonic **4.3.2 Behaviour** - the behaviour can be defined by looking at reports from Barium enema, colonoscopy, MRI, CT **B3** Internal penetrating B1 Non stricturing, non-penetrating **B2 Stricturing** p Perianal disease modifier

Section 5 - Hypersensitivity Reaction History Study code 5.1 Which thiopurine was suspected of causing the hypersensitivity reaction? **Azathioprine** Mercaptopurine 5.2 Date thiopurine first commenced 5.3 Maximum dose of thiopurine in 1 month prior to the hypersensitivity reaction 5.3.1 Date when this maximum dose was started 5.4 Presentation 5.4.1 Symptoms Date of onset of symptoms Please tick all symptoms that apply: Fever Joint pain Muscle ache or pain Headache **Fatigue** General malaise Rash Nausea Vomiting Diarrhoea Other (please indicate)

days

Approximate duration of symptoms

Section 5 - Hypersensitivity Reaction History Study code

5.5 Blood test results

	Date	ALT	Date	Bilirubin	Date	wcc	Date	CRP
Normal range for your lab	dd/mm/yyyy		dd/mm/ yyyy		dd/mm/ yyyy		dd/mm/ yyyy	
Baseline (last blood test before starting thiopurine)	dd/mm/yyyy		dd/mm/ yyyy		dd/mm/ yyyy		dd/mm/ yyyy	
Worst blood test during presentation of symptoms	dd/mm/yyyy		dd/mm/ yyyy		dd/mm/ yyyy		dd/mm/ yyyy	
Blood test >2 weeks after drug withdrawal	dd/mm/yyyy		dd/mm/ уууу		dd/mm/ Уууу		dd/mm/ yyyy	

Yes	No	Unknown	
If yes, date of	admission (dd / mm / yyyy	
Date of dischar	rge (dd / mm / yyyy	
Details			

5.7 Tests conducted for investigation of hypersensitivity reaction

	Date	Please specify further details if positive or abnormal finding
None	dd/mm/yyyy	
Blood cultures	dd/mm/yyyy	
Urine culture	dd/mm/yyyy	
X-ray	dd/mm/yyyy	
СТ	dd/mm/yyyy	
MRI	dd/mm/yyyy	
Ultrasound	dd/mm/yyyy	

Sec	on 6 - Supplementary Information Study code
6.1	Vas the patient ever re-challenged with a thiopurine?
	Yes No Unknown
	yes:
	dd / mm / yyyy
	hiopurine used: Azathioprine Mercaptopurine Not known
	Outcome:
	Tolerated (no adverse reaction)
	Dose tolerated
	Not tolerated
	Adverse reaction (please give details)
	Was this similar to the previous reaction?
	dd / mm / yyyy
6.2	Vhat is the individual's thiopurine methytransfererase (TPMT) genotype/ctivity?
	Genotype Level (u/ml)
	Activity: Absent
	Low (carrier)
	Normal
	High

Not done

Section 6 - Supplementary Information Study code 6.3 Has the individual ever experienced any other adverse effects attributed to azathioprine/mercaptopurine? Yes No Unknown If yes, please record below **6.3.1 Leucopenia** - please give lowest WCC with dates 6.3.2 Pancreatitis - please give peak serum amylase/lipase and laboratory reference and dates 6.3.3 Liver injury - please give peak ALT/Bilirubin 6.4 Other comments If you have any other comments regarding this patient, please give them here.

Section 7 - Other Dru	ıg History
-----------------------	------------

Study code	
------------	--

7.1 Please record below the concomitant medication taken in the 7 days prior to the commencement of the hypersensitivity reaction.

Drug name	Dose, route and frequency	Start date	Stop date
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy
		dd / mm / yyyy	dd / mm / yyyy

ONCE SIGNED, NO FURTHER CHANGES CAN BE MADE TO THIS CRF WITHOUT A SIGNED DATA QUERY FORM